About this trial
To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety. Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut. All participants will be put in a standard fear conditioning paradigm where they are conditioned to fear a face that occasionally is followed by a shock to their wrist. The other face never is paired with a shock. After everybody learns this, half of the participants will receive 600 mg CBD Isolate Gel Capsules one time, and the other half will receive a placebo dose. Participants will then be presented with the faces with no shocks, and the rate and duration of extinction as measured by electrodermal response as well as subjective fear ratings via a visual analogue scale will be examined. It is hypothesized that participants that receive CBD will display enhanced extinction compared to the placebo group, as evidenced by reduced electrodermal response and reduced visual analogue fear ratings.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
18-50 years of age
Disqualifiers
Difficulties seeing a computer screen
Anyone currently taking CBD within the last 24 hours.
Anyone using any cannabis product within the last 24 hours.
Heart problems or heart disease
Trial design
Factorial
Treatments tested in this trial
Cannabidiol Oral Product
DrugParticipants will receive a one-time dose of 600 mg Cannabidiol Isolate Gel Capsules in the form of six 100mg capsules.
Placebo
Other interventionParticipants will receive a one-time dose of placebo capsules in the form of six capsules.
Treatment groups
Trial outcomes
Primary outcomes
Electrodermal activity
Electrodermal response as measured by galvanic skin response electrodes that are attached to two of the fingers via sticker electrodes. These passively measure the conductance of the sweat glands on the fingers.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.